Contribution to the constitutive activation of NFKB pathway [28], the rescue of B cells with crippled mutations from apoptosis [26], promotion of cell proliferation and growth [27] and novel functions assigned to lytic proteins such as ZEBRA [29] could contribute to the progression of tumor and response to therapy in EBV-positive cHL. This evidence concerns the gene NFKB1 and neoplasm.